Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What is the anticipated market size of the gene silencing industry over the next few years?
The gene silencing market size has grown rapidly in recent years. It will grow from $5.97 billion in 2024 to $6.75 billion in 2025 at a compound annual growth rate (CAGR) of 13.0%. The growth in the historic period can be attributed to growing research in genetic therapies, early breakthroughs in RNA interference, increasing prevalence of genetic disorders, rising investment in biotechnology, and growing biopharmaceutical manufacturing capabilities.
The gene silencing market size is expected to see rapid growth in the next few years. It will grow to $10.95 billion in 2029 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to expanding applications in rare diseases, technological advancements in delivery systems, increasing demand for personalized medicine, supportive government initiatives, and growing partnerships between pharma and biotech companies. Major trends in the forecast period include the development of targeted gene therapies, the rise of CRISPR-based silencing approaches, the increasing focus on rare and orphan diseases, the emergence of nanoparticle delivery technologies, and the expansion into agricultural gene silencing applications.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24224&type=smp
What emerging drivers are expected to shape the future of the gene silencing market?
The rising prevalence of genetic disorders is expected to propel the growth of the gene silencing market going forward. Genetic disorders refer to health conditions caused by abnormalities in an individual’s DNA. They are increasingly being identified due to advances in diagnostic technologies, heightened awareness, and broader access to genetic testing. The rising genetic disorders are due to increasing parental age, which elevates the risk of genetic mutations being passed to offspring. Gene silencing offers a promising approach to treating genetic disorders by selectively shutting down the expression of faulty or disease-causing genes. For instance, in August 2023, according to Down Syndrome UK, a UK-based charity, Down syndrome affects an estimated 40,000 people in the UK, with approximately 1 in every 800 babies born with the condition. Therefore, the rising prevalence of genetic disorders is driving the growth of the gene silencing market.
What emerging segments are shaping the future landscape of the gene silencing industry?
The gene silencing market covered in this report is segmented –
1) By Type: Transcriptional, Post-Transcriptional, Meiotic
2) By Gene Silencing: RNA Interference (RNAi), Antisense Oligonucleotides (ASOs), Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Or Cas9 -Based Gene Silencing, Other Gene Silencings
3) By Application: Neurology, Oncology, Infectious Diseases, Metabolic Diseases, Therapeutics Manufacturing, Other Applications
4) By End-Users: Pharmaceutical And Biotechnology Companies, Research Institutes and Academic Centers, Hospitals, Clinics, Other End-Users
Subsegments:
1) By Transcriptional: DNA Methylation, Histone Modification
2) By Post-Transcriptional: RNA Interference (RNAi), Antisense Oligonucleotides, MicroRNA (miRNA) Mediated Silencing
3) By Meiotic: Meiotic Gene Conversion, Transposable Element Silencing
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/gene-silencing-global-market-report
What are the top market trends driving innovation in the gene silencing industry?
Major companies operating in the gene silencing market are focusing on developing innovative technologies, such as small interfering RNA (siRNA), to enhance precision and efficacy in gene therapy. Small interfering RNA (siRNA) refers to a type of RNA molecule that plays a critical role in the RNA interference (RNAi) pathway by binding to specific messenger RNA (mRNA) and promoting its degradation, preventing the production of disease-causing proteins. For instance, in October 2024, Judo Bio Inc., a US-based biotechnology company, launched siRNA, a next-generation drug using small interfering RNA (siRNA) to silence genes. The unique features include proprietary delivery systems such as lipid nanoparticles or conjugated ligands that ensure efficient uptake by specific cells or tissues and AI-driven platforms that accelerate the identification of viable gene targets.
How are key players in the gene silencing market strengthening their market position?
Major companies operating in the gene silencing market are Roche Holding AG, Merck & Co. Inc., AstraZeneca plc, Novartis International AG, Thermo Fisher Scientific Inc., Danaher Corporation, Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., Bio-Techne Corporation, Alnylam Pharmaceuticals Inc., GenScript Biotech Corporation, Oxford BioMedica plc, Ionis Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., New England Biolabs Inc., Quark Pharmaceuticals Inc., Sirion Biotech GmbH, Benitec Biopharma Limited, GeneCopoeia Inc., Revvity Inc.
Which geographic areas are contributing significantly to the growth of the gene silencing sector?
North America was the largest region in the gene silencing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene silencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Gene Silencing Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/customise?id=24224&type=smp
Need Customized Data On Gene Silencing Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24224&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
